Clinical utility of Metabolon's Quantose IR test to be showcased at ADA meeting

MetabolonJun 12 2012

Metabolon, Inc. announces that the clinical utility of the Company's lead diagnostic product Quantose™ IR will be featured in five poster presentations at the 72^nd Annual Scientific Sessions of the American Diabetes Association (ADA) being held June 8-12 in Philadelphia. Quantose IR is a fasting blood test to measure insulin resistance (IR). The test measures levels of three novel non-glycemic biomarkers and insulin to detect prediabetes earlier and with greater sensitivity than traditional glycemic markers such as glucose and Hemoglobin A1C.

"This marks our fourth consecutive ADA annual meeting and our expanded presence this year reflects our Company's continued focus on developing diagnostic tests related to metabolic disease," said John Ryals, President and CEO of Metabolon. "As insulin resistance is known to precede Type 2 diabetes by up to 10 years, Quantose IR offers clinicians a tool for identifying patients at greatest risk for disease progression long before glycemic markers show evidence of dysregulation. Clinicians seeking to intervene in this high-risk group will be provided unique pathophysiological insight helpful in tailoring treatments to individual patients. Our Quantose IR test also provides a useful therapeutic monitoring tool to complement traditional markers in gauging treatment effectiveness due to its non-glycemic markers tracking so closely with changing insulin sensitivity."

The following five abstracts related to Metabolon's ongoing research and development efforts associated with Quantose IR will be featured at the ADA meeting:

"Early metabolic markers of the development of dysglycemia and Type 2 diabetes and their physiological significance"

• Alpha-hydroxybutyrate (AHB) and linoleoyl-glycerophosphocholine (L-GPC) are described as novel circulatory markers of insulin resistance, with clinical outcome data demonstrating their predictive risk to prediabetes and Type 2 diabetes and response to intervention. Additional studies are presented that examine the Quantose IR biomarker's physiological significance such as their bioactivity on insulin secretion. Abstract # 1600-P, to be presented by Dr. Walter Gall during the Monday, June 11^th 12-2pm poster session.

"Pioglitazone improves insulin sensitivity by modulating novel biomarkers in impaired glucose tolerance" (Audio poster tour)

• Top-ranking insulin sensitivity biomarkers are measured in the T2D prevention study ACT NOW. The purpose of the study was to describe the response of the novel Quantose IR metabolites and its algorithm IR signature to pioglitazone pharmacotherapy and provide context of these observations in a diabetes prevention clinical setting. Abstract # 1182-P, to be presented by Dr. Walter Gall during the Saturday, June 9^th 11:30am-1:30pm poster session and the Sunday, June 10^th 12-1pm guided audio tour.

"Metabolomic profile associated with hepatic insulin resistance in nondiabetic subjects: results from RISC study" (Audio poster tour)

• Quantose IR metabolites AHB and L-GPC are associated with hepatic insulin resistance, non-alcoholic fatty liver disease and NASH, further validating the clinical importance of measuring these novel biomarkers associated with IR-related disease outcomes. Abstract # 1791-P, to be presented by Dr. Amalia Gastadelli during the Monday, June 11^th 12-2pm poster session.

"Effect of aging and exercise on novel insulin sensitivity marker linoleoyl-glycerophosphocholine" (Audio poster tour)

• Lifestyle intervention study with sedentary IR subjects demonstrate the response of Quantose IR metabolites AHB and L-GPC to aerobic exercise and further show associations of L-GPC with aging. Abstract # 714-P, to be presented by Dr. Jose de Jesus Garduno Garcia during the Monday, June 11^th 12-2pm poster session and the Monday, June 11^th 1-2pm guided audio tour.

"Genetic variants associated with diabetes related circulating metabolite levels and their role in type 2 diabetes and insulin sensitivity"

• Genome-wide association studies were carried out with the RISC and Botnia prospective studies to identify and validate associations of genes and metabolites related to glycine, the top-ranking amino acid related to insulin sensitivity and proximal to Quantose IR metabolite AHB biosynthesis. Abstract # 1526-P, to be presented by Dr. Weijia Xie during the Monday, June 11^th 12-2pm poster session.